GlassScriptPhysician profile
Ting-Lin Yang
NPI 1154771954
$124,294.36
in general payments reported to CMS, 2019-2025
25 companies · $79K in 2025
The $79K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $204 · 2021: $314 · 2022: $1,545 · 2023: $8,331 · 2024: $35K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Travel and Lodging: $12K · Consulting Fee: $12K · Food and Beverage: $10K · Education: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,862.50 |
| Travel and Lodging | $12,459.07 |
| Consulting Fee | $11,632.50 |
| Food and Beverage | $10,294.43 |
| Education | $633.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $64,571.50 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Lilly USA, LLC | $40,858.23 | 2022-2025 | Ebglyss, Taltz, Zepbound |
| Regeneron Healthcare Solutions, INC. | $4,248.94 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $4,209.39 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $3,334.59 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $2,221.81 | 2023-2024 | Zoryve |
| Incyte Corporation | $1,089.86 | 2022-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $573.76 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $475.64 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $475.14 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $396.03 | 2024-2025 | Nemluvio, Aklief, Oracea |
| Sun Pharmaceutical Industries INC. | $343.34 | 2023-2025 | Ilumya |
| Amgen INC. | $243.02 | 2022-2024 | Otezla, Enbrel |
| Dermavant Sciences, INC. | $231.35 | 2023-2024 | Vtama |
| Allergan, INC. | $204.37 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $164.36 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $133.58 | 2023-2025 | |
| Pfizer INC. | $116.68 | 2022-2023 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $98.28 | 2019 | |
| Blueprint Medicines Corporation | $76.86 | 2023 | Ayvakit |
| Organon LLC | $43.67 | 2025 | Vtama |
| Krystal Biotech INC | $41.06 | 2025 | Vyjuvek |
| Genentech USA, INC. | $23.29 | 2024 | Erivedge |
| Regeneron Pharmaceuticals, INC. | $20.61 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ting-Lin Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.